Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Burioni, Roberto ^a   Mancini, Nicasio ^a   De Marco, Donata ^a   Clementi, Nicola ^a   Perotti, Mario ^a   Nitti, Giovanni ^a   Sassi, Monica ^a   Canducci, Filippo ^a   Shvela, Krisha ^b   Bagnarelli, Patrizia ^c   Mascola, John R ^b   Clementi, Massimo ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; BINDING SITE; CONCEPT ANALYSIS; CONTROLLED STUDY; DRUG DESIGN; DRUG PURIFICATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYBRIDOMA; MOUSE; NONHUMAN; PROTEIN DETERMINATION; VACCINE PRODUCTION; VALIDATION STUDY; VIRUS STRAIN; ANIMAL; ANTIBODY PRODUCTION; BLOOD; DRUG EFFECT; IMMUNOLOGY; MOLECULAR MIMICRY; RABBIT;

HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; MUS; ORYCTOLAGUS CUNICULUS;

AIDS VACCINES; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIGENS, CD4; EPITOPES; HIV ENVELOPE PROTEIN GP120; HUMANS; MICE; MOLECULAR MIMICRY; RABBITS;

EID: 54849437925     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003423     Document Type: Article

References (41)

1. Pantaleo G, Koup RA (2004) Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 10: 806-810.
2. Plotkin SA (2001) Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 20: 63-75.
3. Huber M, Trkola A (2007) Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 262: 5-25.
4. Srivastava IK, Ulmer JB, Barnett SW (2005) Role of neutralizing antibodies in protective immunity against HIV. Hum Vaccin 1: 45-60.
5. Zolla-Pazner S (2004) Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 4: 199-210.
6. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233-236.
7. McMichael AJ (2006) HIV vaccines. Annu Rev Immunol 24: 227-255.
8. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, et al. (1996) Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 173: 340-348.
9. Haynes BF, Montefiori DC (2006) Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines 5: 579-595.
10. Pantophlet R, Burton DR (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24: 739-769.
11. Johnston MI, Fauci AS (2007) An HIV vaccine-evolving concepts. N Engl J Med 356: 2073-2081.
12. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659.
13. Olshevsky U, Helseth E, Furman C, Li J, Haseltine W, et al. (1990) Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol 64: 5701-5707.
14. Thali M, Olshevsky U, Furman C, Gabuzda D, Posner M, et al. (1991) Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol 65: 6188-6193.
15. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al. (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705-711.
16. Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, et al. (2006) Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. Aids 20: 1923-1930.
17. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, et al. (2007) Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 81: 6548-6562.
18. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, et al. (2007) Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13: 1032-1034.
19. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732-737.
20. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75: 8340-8347.
21. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, et al. (2000) Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci U S A 97: 9026-9031.
22. Parren PW, Burton DR, Sattentau QJ (1997) HIV-1 antibody-debris or virion? Nat Med 3: 366-367.
23. Wyatt R, Sodroski J (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888.
24. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, et al. (2005) Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433: 834-841.
25. Dey B, Pancera M, Svehla K, Shu Y, Xiang SH, et al. (2007) Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J Virol 81: 5579-5593.
26. Xiang SH, Kwong PD, Gupta R, Rizzuto CD, Casper DJ, et al. (2002) Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 76: 9888-9899.
27. Barbas CF 3rd, Bjorling E, Chiodi F, Dunlop N, Cababa D, et al. (1992) Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A 89: 9339-9343.
28. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027.
29. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 13232-13252.
30. Mantis NJ, Palaia J, Hessell AJ, Mehta S, Zhu Z, et al. (2007) Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region. J Immunol 179: 3144-3152.
31. Dorgham K, Dogan I, Bitton N, Parizot C, Cardona V, et al. (2005) Immunogenicity of HIV type 1 gp120 CD4 binding site phage mimotopes. AIDS Res Hum Retroviruses 21: 82-92.
32. Saphire EO, Montero M, Menendez A, van Houten NE, Irving MB, et al. (2007) Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. J Mol Biol 369: 696-709.
33. Humbert M, Antoni S, Brill B, Landersz M, Rodes B, et al. (2007) Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. Eur J Immunol 37: 501-515.
34. Chen X, Scala G, Quinto I, Liu W, Chun TW, et al. (2001) Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nat Med 7: 1225-1231.
35. Scala G, Chen X, Liu W, Telles JN, Cohen OJ, et al. (1999) Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. J Immunol 162: 6155-6161.
36. Burton DR, Parren PWHI (2000) Vaccine and the induction of functional antibodies: time to look beyond the molecules of natural infection? Nat Med 6: 123-125.
37. Mascola JR, D'Souza P, Gilbert P, Hahn BH, Haigwood NL, et al. (2005) Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 79: 10103-10107.
38. Hariharan K, Nara PL, Caralli VM, Norton FL, Haigwood N, et al. (1993) Analysis of the cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected asymptomatic individuals. J Virol 67: 953-960.
39. Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, et al. (2006) Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 80: 1414-1426.
40. Burioni R, Plaisant P, Bugli F, Delli Carri V, Clementi M, et al. (1998) A vector for the expression of recombinant monoclonal Fab fragments in bacteria. J Immunol Methods 217: 195-199.
41. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108-10125.